Overt testicular disease (OTD) at diagnosis is not associated with a poor prognosis in childhood acute lymphoblastic leukemia: Results of the EORTC CLG study 58881

Pediatric Blood and Cancer

Volumn 49, Issue 3, 2007, Pages 344-348

  Sirvent, Nicolas ^a,g   Suciu, Stefan ^b   Bertrand, Yves ^c   Uyttebroeck, Anne ^d   Lescoeur, Brigitte ^e   Otten, Jacques ^f  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b EORTC DATA CENTER   (Belgium)

^c HÔPITAL DEBROUSSE   (France)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^g CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Acute lymphoblastic leukemia; Childhood; Prognostic factor; Testicular involvement

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; DRUG MEGADOSE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TESTIS DISEASE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FRANCE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; MULTIVARIATE ANALYSIS; PORTUGAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK; SURVIVAL RATE; TESTICULAR NEOPLASMS;

EID: 34547743108     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20716     Document Type: Article

References (19)

1. Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology, 4th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2002.
2. Gajjar A, Ribeiro R, Mahmoud H, et al. Overt testicular disease at diagnosis is associated with high risk features and a poor prognosis in patients with childhood acute lymphoblastic leukemia. Cancer 1996;78:2437-2442.
3. Dordelmann M, Reiter A, Zimmermann M, et al. Intermediate dose methotrexate is as effective as high-dose methotrexate in preventing isolated testicular relapse in childhood acute lymphoblastic leukemia. J Ped Hematol Oncol 1998;20:444-450.
4. Langermann HJ, Henze G, Wulf M, et al. Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: Prognostic significance and practical application. Klin Padiatr 1982;194:209-213.
5. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-3322.
6. Millot F, Suciu S, Philippe N, et al. Value of high-dose Ara-C during the interval-therapy of a BFM-based protocol in increased risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the EORTC 58881 randomized phase III trial. JCO 2001;19:1935-1942.
7. Duval M, Suciu S, Ferster A, et al. Comparative toxicity and efficacy of E coli-asparaginase and Erwinia-asparaginase in childhood lymphoid malignancies: Results of an EORTC-CLCG phase 3 randomized trial. Blood 2002;8:2734-2739.
8. Vilmer E, Suciu S, Ferster A, et al. Long-term results of three randomized trials in childhood acute lymphoblastic leukemia: A CLCG-EORTC report. Leukemia 2000;14:2257-2266.
9. van der Werff Ten Bosch J, Suciu S, Thyss A, et al. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin lymphoma: Final results of a randomized phase III trial (58881) of the EORTC CLG. Leukemia 2005; [Epub ahead of print].
10. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
11. Kalbfleisch JD, Prentice RL. The clinical analysis of failure time data. In: Kalbfleish JD, editor. Wiley Series in Probabilities and Statistics. 2nd edition. New-Jersey, USA: Wiley Inter-Science; 2002.
12. Cox DR, Hinkley DV. Theoretical statistics. New York, NY: Chapman and Hall; 1974. pp 323-324.
13. Russo A, Schiliro G. The enigma of testicular leukemia: A critical review. Med Pediatr Oncol 1986;14:300-305.
14. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000;14:2286-2294.
15. Riccardi R, Vigersky RA, Barnes S, et al. Methotrexate levels in the interstitial space and seminiferous tubule of rat testis. Cancer Res 1982;42:1617-1619.
16. Freeman AI, Boyett JM, Glicksman AS, et al. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: A 10-year follow-up. Med Pediatr Oncol 1997;28:98-107.
17. Dalle JH, Mechinaud F, Michon J, et al. Testicular disease in childhood B-cell non-hodgkin lymphoma: The French Society of Pediatric Oncology experience. J Clin Oncol 2001;19:2397-2403.
18. Steenbergen EJ, Verhagen OJ, van Leeuwen EF, et al. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia 1995;9:1726-1734.
19. Baum E, Heyn R, Nesbit M, et al. Occult abdominal involvement with apparently isolated testicular relapse in children with acute lymphocytic leukemia. Am J Pediatr Hematol Oncol 1984;6:343-346.